APA (7th ed.) Citation

Tang, Q., Zhang, X., Zhu, X., Xu, H., Song, G., Lu, J., . . . Wang, J. (2024). Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single‐arm, exploratory phase II trial. Cancer Medicine, 13(18), 1. https://doi.org/10.1002/cam4.70206

Chicago Style (17th ed.) Citation

Tang, Qinglian, et al. "Camrelizumab in Combination with Doxorubicin, Cisplatin, Ifosfamide, and Methotrexate in Neoadjuvant Treatment of Resectable Osteosarcoma: A Prospective, Single‐arm, Exploratory Phase II Trial." Cancer Medicine 13, no. 18 (2024): 1. https://doi.org/10.1002/cam4.70206.

MLA (9th ed.) Citation

Tang, Qinglian, et al. "Camrelizumab in Combination with Doxorubicin, Cisplatin, Ifosfamide, and Methotrexate in Neoadjuvant Treatment of Resectable Osteosarcoma: A Prospective, Single‐arm, Exploratory Phase II Trial." Cancer Medicine, vol. 13, no. 18, 2024, p. 1, https://doi.org/10.1002/cam4.70206.